A novel vitamin D derivative activates bone morphogenetic protein signaling in MCF10 breast epithelial cells

Molecular Pharmacology

Volumn 69, Issue 6, 2006, Pages 1840-1848

  Hong, Jin Lee ^a   Wislocki, Andrew ^a   Goodman, Catherine ^a   Ji, Yan ^a   Ge, Rongrong ^b   Maehr, Hubert ^a   Uskokovic, Milan ^a   Reiss, Michael ^b   Suh, Nanjoo ^a  

^a RUTGERS UNIVERSITY   (United States)

^b RUTGERS CANCER INSTITUTE OF NEW JERSEY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

[1ALPHA,25 DIHYDROXY 16,23(Z) DIENE 26,27 HEXAFLUORO 19 NOR CHOLECALCIFEROL]; [1ALPHA,25 DIHYDROXY 20S 21(3 HYDROXY 3 METHYL BUTYL) 23 YNE 26,27 HEXAFLUOROCHOLECALCIFEROL]; BONE MORPHOGENETIC PROTEIN; BONE MORPHOGENETIC PROTEIN 2; BONE MORPHOGENETIC PROTEIN 6; COLECALCIFEROL DERIVATIVE; MESSENGER RNA; NOGGIN; RO 2198; RO 3582; SMAD1 PROTEIN; SMAD2 PROTEIN; SMAD5 PROTEIN; SMAD6 PROTEIN; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA ANTIBODY; UNCLASSIFIED DRUG;

ARTICLE; BREAST ADENOCARCINOMA; BREAST EPITHELIUM; DRUG ACTIVITY; DRUG ANTAGONISM; DRUG EFFECT; DRUG MECHANISM; DRUG STRUCTURE; EPITHELIUM CELL; HUMAN; HUMAN CELL; INHIBITION KINETICS; METASTASIS INHIBITION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN INDUCTION; PROTEIN INTERACTION; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; PROTEIN SYNTHESIS; SIGNAL TRANSDUCTION; UPREGULATION;

ANTIBODIES; BONE MORPHOGENETIC PROTEINS; BREAST; CALCITRIOL; CARRIER PROTEINS; CELL LINE, TUMOR; CHOLECALCIFEROL; EPITHELIAL CELLS; FEMALE; HUMANS; PHOSPHORIC MONOESTER HYDROLASES; PHOSPHORYLATION; SIGNAL TRANSDUCTION; SMAD PROTEINS; TRANS-ACTIVATION (GENETICS); TRANSFORMING GROWTH FACTOR BETA;

EID: 33745159390     PISSN: 0026895X     EISSN: 15210111     Source Type: Journal    
DOI: 10.1124/mol.105.022079     Document Type: Article

References (39)

1. Bettoun DJ, Lu J, Khalifa B, Yee Y, Chin WW, and Nagpal S (2004) Ligand modulates VDR-Ser/Thr protein phosphatase interaction and p70S6 kinase phosphorylation in a cell-context-dependent manner. J Steroid Biochem Mol Biol 89-90:195-198.
2. Cao Z, Flanders KC, Bertolette D, Lyakh LA, Wurthner JU, Parks WT, Letterio JJ, Ruscetti FW, and Roberts AB (2003) Levels of phospho-Smad2/3 are sensors of the interplay between effects of TGF-β and retinoic acid on monocytic and granulocytic differentiation of HL-60 cells. Blood 101:498-507.
3. Chen D, Zhao M, and Mundy GR (2004) Bone morphogenetic proteins. Growth Factors 22:233-241.
4. Derynck R and Zhang YE (2003) Smad-dependent and Smad-independent pathways in TGF-β family signalling. Nature (Lond) 425:577-584.
5. Falk LA, De Benedetti F, Lohrey N, Birchenall-Roberts MC, Ellingsworth LW, Faltynek CR, and Ruscetti FW (1991) Induction of transforming growth factor-β1 (TGF-β1), receptor expression and TGF-β1 protein production in retinoic acid-treated HL-60 cells: possible TGF-β1-mediated autocrine inhibition. Blood 77:1248-1255.
6. Ghosh-Choudhury N, Ghosh-Choudhury G, Celeste A, Ghosh PM, Moyer M, Abboud SL, and Kreisberg J (2000) Bone morphogenetic protein-2 induces cyclin kinase inhibitor p21 and hypophosphorylation of retinoblastoma protein in estradiol-treated MCF-7 human breast cancer cells. Biochim Biophys Acta 1497:186-196.
7. Hallahan AR, Pritchard JI, Chandraratna RA, Ellenbogen RG, Geyer JR, Overland RP, Strand AD, Tapscott SJ, and Olson JM (2003) BMP-2 mediates retinoid-induced apoptosis in medulloblastoma cells through a paracrine effect. Nat Med 9:1033-1038.
8. Haramis AP, Begthel H, van den Born M, van Es J, Jonkheer S, Offerhaus GJ, and Clevers H (2004) De novo crypt formation and juvenile polyposis on BMP inhibition in mouse intestine. Science (Wash DC) 303:1684-1686.
9. Hata A, Lagna G, Massague J, and Hemmati-Brivanlou A (1998) Smad6 inhibits BMP/Smad1 signaling by specifically competing with the Smad4 tumor suppressor. Genes Dev 12:186-197.
10. Hatakeyama S, Ohara-Nemoto Y, Kyakumoto S, and Satoh M (1996) Retinoic acid enhances expression of bone morphogenetic protein-2 in human adenocarcinoma cell line (HSG-S8). Biochem Mol Biol Int 38:1235-1243.
11. He XC, Zhang J, Tong WG, Tawfik O, Ross J, Scoville DH, Tian Q, Zeng X, He X, Wiedemann LM, et al. (2004) BMP signaling inhibits intestinal stem cell self-renewal through suppression of Wnt-β-catenin signaling. Nat Genet 36:1117-1121.
12. Helms MW, Packeisen J, August C, Schittek B, Boecker W, Brandt BH, and Buerger H (2005) First evidence supporting a potential role for the BMP/SMAD pathway in the progression of oestrogen receptor-positive breast cancer. J Pathol 206:366-376.
13. Horvath LG, Henshall SM, Kench JG, Turner JJ, Golovsky D, Brenner PC, O'Neill GF, Kooner R, Stricker PD, Grygiel JJ, et al. (2004) Loss of BMP2, Smad8 and Smad4 expression in prostate cancer progression. Prostate 59:234-242.
14. Imamura T, Takase M, Nishihara A, Oeda E, Hanai J, Kawabata M, and Miyazono K (1997) Smad6 inhibits signalling by the TGF-β superfamily. Nature (Lond) 389:622-626.
15. Ishida W, Hamamoto T, Kusanagi K, Yagi K, Kawabata M, Takehara K, Sampath TK, Kato M, and Miyazono K (2000) Smad6 is a Smad1/5-induced Smad inhibitor. Characterization of bone morphogenetic protein-responsive element in the mouse Smad6 promoter. J Biol Chem 275:6075-6079.
16. Kawabata M, Imamura T, and Miyazono K (1998) Signal transduction by bone morphogenetic proteins. Cytokine Growth Factor Rev 9:49-61.
17. Koli K and Keski-Oja J (1995) 1,25-Dihydroxyvitamin D3 enhances the expression of transforming growth factor β1 and its latent form binding protein in cultured breast carcinoma cells. Cancer Res 55:1540-1546.
18. Matsuda T, Yamamoto T, Muraguchi A, and Saatcioglu F (2001) Cross-talk between transforming growth factor-β and estrogen receptor signaling through Smad3. J Biol Chem 276:42908-42914.
19. Miller FR (2000) Xenograft models of premalignant breast disease. J Mammary Gland Biol Neoplasia 5:379-391.
20. Miyazaki H, Watabe T, Kitamura T, and Miyazono K (2004) BMP signals inhibit proliferation and in vivo tumor growth of androgen-insensitive prostate carcinoma cells. Oncogene 23:9326-9335.
21. Miyazawa K, Shinozaki M, Hara T, Furuya T, and Miyazono K (2002) Two major Smad pathways in TGF-β superfamily signalling. Genes Cells 7:1191-1204.
22. Miyazono K, Maeda S, and Imamura T (2005) BMP receptor signaling: transcriptional targets, regulation of signals and signaling cross-talk. Cytokine Growth Factor Rev 16:251-263.
23. Murakami G, Watabe T, Takaoka K, Miyazono K, and Imamura T (2003) Cooperative inhibition of bone morphogenetic protein signaling by Smurf1 and inhibitory Smads. Mol Biol Cell 14:2809-2817.
24. Pardali K, Kowanetz M, Heldin CH, and Moustakas A (2005) Smad pathway-specific transcriptional regulation of the cell cycle inhibitor p21(WAF1/Cip1). J Cell Physiol 204:260-272.
25. Pouliot F and Labrie C (2002) Role of Smad1 and Smad4 proteins in the induction of p21WAF1, Cip1 during bone morphogenetic protein-induced growth arrest in human breast cancer cells. J Endocrinol 172:187-198.
26. Raida M, Clement JH, Ameri K, Han C, Leek RD, and Harris AL (2005) Expression of bone morphogenetic protein 2 in breast cancer cells inhibits hypoxic cell death. Int J Oncol 26:1465-1470.
27. Reinholz MM, Iturria SJ, Ingle JN, and Roche PC (2002) Differential gene expression of TGF-β family members and osteopontin in breast tumor tissue: analysis by real-time quantitative PCR. Breast Cancer Res Treat 74:255-269.
28. Santner SJ, Dawson PJ, Tait L, Soule HD, Eliason J, Mohamed AN, Wolman SR, Heppner GH, and Miller FR (2001) Malignant MCF10CA1 cell lines derived from premalignant human breast epithelial MCF10AT cells. Breast Cancer Res Treat 65:101-110.
29. Suh N, Honda T, Finlay HJ, Barchowsky A, Williams C, Benoit NE, Xie QW, Nathan C, Gribble GW, and Sporn MB (1998) Novel triterpenoids suppress inducible nitric oxide synthase (iNOS) and inducible cyclooxygenase (COX-2) in mouse macrophages. Cancer Res 58:717-723.
30. Suh N, Roberts AB, Birkey Reffey S, Miyazono K, Itoh S, ten Dijke P, Heiss EH, Place AE, Risingsong R, Williams CR, et al. (2003) Synthetic triterpenoids enhance transforming growth factor β/Smad signaling. Cancer Res 63:1371-1376.
31. Sutton AL and MacDonald PN (2003) Vitamin D: more than a "bone-a-fide" hormone. Mol Endocrinol 17:777-791.
32. Tang B, Vu M, Booker T, Santner SJ, Miller FR, Anver MR, and Wakefield LM (2003) TGF-β switches from tumor suppressor to prometastatic factor in a model of breast cancer progression. J Clin Investig 112:1116-1124.
33. Ten Dijke P, Goumans MJ, Itoh F, and Itoh S (2002) Regulation of cell proliferation by Smad proteins. J Cell Physiol 191:1-16.
34. Tian F, DaCosta Byfield S, Parks WT, Yoo S, Felici A, Tang B, Piek E, Wakefield LM, and Roberts AB (2003) Reduction in Smad2/3 signaling enhances tumorigenesis but suppresses metastasis of breast cancer cell lines. Cancer Res 63:8284-8292.
35. 3 that resist metabolism through C-24 oxidation and C-3 epimerization pathways. Steroids 66:463-471.
36. Villanueva A, Garcia C, Paules AB, Vicente M, Megias M, Reyes G, de Villalonga P, Agell N, Lluis F, Bachs O, et al. (1998) Disruption of the antiproliferative TGF-β signaling pathways in human pancreatic cancer cells. Oncogene 17:1969-1978.
37. 3 with enhanced transcriptional activity. Biochem Pharmacol 67:1327-1336.
38. Yanagi Y, Suzawa M, Kawabata M, Miyazono K, Yanagisawa J, and Kato S (1999) Positive and negative modulation of vitamin D receptor function by transforming growth factor-β signaling through Smad proteins. J Biol Chem 274:12971-12974.
39. Yanagisawa J, Yanagi Y, Masuhiro Y, Suzawa M, Watanabe M, Kashiwagi K, Toriyabe T, Kawabata M, Miyazono K, and Kato S (1999) Convergence of transforming growth factor-β and vitamin D signaling pathways on SMAD transcriptional coactivators. Science (Wash DC) 283:1317-1321.